ATXS

ATXS

USD

Astria Therapeutics Inc. Common Stock

$12.250+0.120 (0.989%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$12.130

Máximo

$12.390

Mínimo

$12.110

Volumen

1.43M

Fundamentos de la Empresa

Capitalización de Mercado

691.3M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

1.58M

Bolsa

NGM

Moneda

USD

Rango de 52 Semanas

Mínimo $3.555Actual $12.250Máximo $12.715

Noticias Relacionadas

BusinessWire

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final results from the

Ver más
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
PR Newswire

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HOLX, TRUE, PCH, ATXS on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

Ver más
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HOLX, TRUE, PCH, ATXS on Behalf of Shareholders
Analyst Upgrades

JMP Securities Downgrades Astria Therapeutics to Market Perform

JMP Securities analyst Jonathan Wolleben downgrades Astria Therapeutics from Market Outperform to Market Perform.

Ver más
JMP Securities Downgrades Astria Therapeutics to Market Perform
PR Newswire

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS)

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...

Ver más
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS)
Analyst Upgrades

Jefferies Downgrades Astria Therapeutics to Hold, Lowers Price Target to $13

Jefferies analyst Eun Yang downgrades Astria Therapeutics from Buy to Hold and lowers the price target from $30 to $13.

Ver más
Jefferies Downgrades Astria Therapeutics to Hold, Lowers Price Target to $13
PR Newswire

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS, PCH, RYN on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

PR Newswire

Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

The Ademi Firm is investigating Astria (NASDAQ: ATXS) for possible breaches of fiduciary duty and other violations of law in its transaction with...

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.